RNA m6A methylation regulatory mechanism of resveratrol in premature senescence cells DOI Creative Commons

Xinyu Zhang,

Chenyu Zhu,

Luyun Zhang

и другие.

Food Science & Nutrition, Год журнала: 2024, Номер 12(11), С. 9238 - 9251

Опубликована: Сен. 30, 2024

Abstract Resveratrol, a natural compound found in various plants, is known for its anti‐inflammatory, antioxidant, and senescence‐delaying properties. RNA N6‐methyladenosine (m6A) methylation plays crucial role oxidative stress premature cellular senescence processes closely associated with age‐related disorders. However, the anti‐premature via m6A mechanism of resveratrol still not fully understood. In this study, based on model human embryonic lung fibroblasts (HEFs) induced by hydrogen peroxide (H 2 O ), widely accepted caused stress, we explored anti‐aging regulatory effects at level. Our data suggested that significantly delayed increasing cell viability, reducing SA‐β‐gal blue staining rate, ROS levels, senescence‐associated secretory phenotypes (SASP) expression HEFs. Meanwhile, increased whole methyltransferases activity overall level during senescence. Furthermore, three genes CCND2 , E2F1 GADD45B have been identified as main ones regulating resveratrol. Specifically, it decreased level, cells. study provided new clues exploring application field aging.

Язык: Английский

RNA modifications in the progression of liver diseases: from fatty liver to cancer DOI Creative Commons
Simiao Li‐Sauerwine, Wajahat Z. Mehal, Xinshou Ouyang

и другие.

Science China Life Sciences, Год журнала: 2024, Номер 67(10), С. 2105 - 2119

Опубликована: Май 27, 2024

Abstract Non-alcoholic fatty liver disease (NAFLD) has emerged as a prominent global health concern associated with high risk of metabolic syndrome, and impacted substantial segment the population. The spectrum ranges from simple to non-alcoholic steatohepatitis (NASH), which can progress cirrhosis hepatocellular carcinoma (HCC) is increasingly becoming prevalent indication for transplantation. existing therapeutic options NAFLD, NASH, HCC are limited, underscoring urgent need innovative treatment strategies. Insights into gene expression, particularly RNA modifications such N 6 methyladenosine (m A), hold promising avenues interventions. These play integral roles in metabolism cellular functions, encompassing entire NAFLD-NASH-HCC progression. This review will encompass recent insights on diverse modifications, including m A, pseudouridine (ψ), 1 -methyladenosine 5-methylcytidine 5 C) across various species. It uncover their significance crucial aspects steatosis, inflammation, fibrosis, tumorigenesis. Furthermore, prospective research directions implications be explored, advancing our comprehensive understanding intricate interconnected nature these pathological conditions.

Язык: Английский

Процитировано

6

Changes in m6A in Steatotic Liver Disease DOI Open Access
Belinda J. Petri, Matthew C. Cave, Carolyn M. Klinge

и другие.

Genes, Год журнала: 2023, Номер 14(8), С. 1653 - 1653

Опубликована: Авг. 19, 2023

Fatty liver disease is one of the major causes morbidity and mortality worldwide. includes non-alcoholic fatty (NAFLD) steatohepatitis (NASH), now replaced by a consensus group as metabolic dysfunction-associated steatotic (MASLD). While excess nutrition obesity are contributors to liver, underlying mechanisms remain largely unknown therapeutic interventions limited. Reversible chemical modifications in RNA newly recognized critical regulators controlling post-transcriptional gene expression. Among these modifications, N6-methyladenosine (m6A) most abundant regulates transcript abundance disease. Modulation m6A readers, writers, erasers (RWE) impacts mRNA processing, translation, nuclear export, localization, degradation. many studies focus on RWE expression human pathologies, limitations technology bioinformatic methods detect present challenges understanding epitranscriptomic driving progression. In this review, we summarize current detecting specific genes associated with

Язык: Английский

Процитировано

11

Role of N6‐methyladenosine RNA modification in cancer DOI Creative Commons
Yi Qu, Nannan Gao, Shengwei Zhang

и другие.

MedComm, Год журнала: 2024, Номер 5(9)

Опубликована: Сен. 1, 2024

Abstract N6‐methyladenosine (m6A) is the most abundant modification of RNA in eukaryotic cells. Previous studies have shown that m6A pivotal diverse diseases especially cancer. corelates with initiation, progression, resistance, invasion, and metastasis However, despite these insights, a comprehensive understanding its specific roles mechanisms within complex landscape cancer still elusive. This review begins by outlining key regulatory proteins their posttranslational modifications (PTMs), as well role chromatin accessibility transcriptional activity Additionally, it highlights impact progression modulating programmed cell death affecting tumor microenvironment through various cancer‐associated immune Furthermore, discusses how microorganisms can induce enduring epigenetic changes oncogenic effect microorganism‐associated cancers altering modifications. Last, delves into immunotherapy, encompassing therapy, checkpoint blockade, cytokine adoptive transfer direct targeting regulators. Overall, this clarifies multifaceted explores targeted therapies aimed at manipulating modification, aiming to advance research improve patient outcomes.

Язык: Английский

Процитировано

4

Emerging role of m6A modification in fibrotic diseases and its potential therapeutic effect DOI

Wufei Ye,

Xiongwen Lv,

Songsen Gao

и другие.

Biochemical Pharmacology, Год журнала: 2023, Номер 218, С. 115873 - 115873

Опубликована: Окт. 24, 2023

Язык: Английский

Процитировано

9

The Functions of N6-Methyladenosine in Nuclear RNAs DOI
Nadezhda Zhigalova,

Katerina Oleynikova,

Alexey Ruzov

и другие.

Biochemistry (Moscow), Год журнала: 2024, Номер 89(1), С. 159 - 172

Опубликована: Янв. 1, 2024

Язык: Английский

Процитировано

3

The m6A writer KIAA1429 regulates photoaging progression via MFAP4-dependent collagen synthesis DOI Creative Commons
Yuanyuan Liu, Jian Li,

Chenhui Wang

и другие.

BMC Biology, Год журнала: 2024, Номер 22(1)

Опубликована: Сен. 11, 2024

Процитировано

3

The regulatory role of KIAA1429 in epithelial-mesenchymal transition in cervical cancer via mediating m6A modification of BTG2 DOI
Mingyang Wang, Zhiliang Wang, Xiaofeng Zou

и другие.

Cytotechnology, Год журнала: 2025, Номер 77(1)

Опубликована: Янв. 3, 2025

Язык: Английский

Процитировано

0

Emerging importance of m6A modification in liver cancer and its potential therapeutic role DOI
Tao Chen,

Wufei Ye,

Songsen Gao

и другие.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Год журнала: 2025, Номер unknown, С. 189299 - 189299

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0

Reciprocal regulation between m6 A modifications and non-coding RNAs: emerging roles in cancer therapeutic resistance DOI Creative Commons
Dan Fan, Yan Shang, Y. Cong

и другие.

Discover Oncology, Год журнала: 2025, Номер 16(1)

Опубликована: Май 25, 2025

In recent years, the interplay between N6-methyladenosine (m6A) modifications and non-coding RNAs (ncRNAs) has emerged as a pivotal research area, owing to their crucial involvement in pathophysiological mechanisms underlying various diseases. A significant hurdle cancer therapy is therapeutic resistance, which frequently contributes adverse patient outcomes. Recent investigations have underscored vital role that interactions m6A ncRNAs play mediating resistance via MAPK, PI3K/Akt/mTOR, Wnt/β-catenin, HIPPO, NF-κB pathways. This review elucidates how these drive tumor by modulating By dissecting regulatory dynamics context of this aims deepen understanding m6A-ncRNA interaction identify potential targets improve treatment efficacy.

Язык: Английский

Процитировано

0

Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer DOI Open Access
Yu Huang,

Yali Fan,

Ziyi Zhao

и другие.

International Journal of Molecular Sciences, Год журнала: 2023, Номер 24(15), С. 12375 - 12375

Опубликована: Авг. 3, 2023

Ovarian cancer is the deadliest gynecological malignancy of reproductive organs in United States. Cyclin-dependent kinase 1 (CDK1) an important cell cycle regulatory protein that specifically controls G2/M phase transition cycle. RO-3306 a selective, ATP-competitive, and cell-permeable CDK1 inhibitor shows potent anti-tumor activity multiple pre-clinical models. In this study, we investigated effect expression on prognosis patients with ovarian anti-tumorigenic both lines genetically engineered mouse model high-grade serous (KpB model). 147 epithelial cancer, overexpression was significantly associated poor compared low group. inhibited cellular proliferation, induced apoptosis, caused stress, reduced migration. The treatment KpB mice for four weeks showed significant decrease tumor weight under obese lean conditions without obvious side effects. Overall, our results demonstrate inhibition by effectively reduces proliferation growth, providing biological evidence future clinical trials inhibitors cancer.

Язык: Английский

Процитировано

8